UBS Starts Diplomat Pharmacy (DPLO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- JPMorgan upgrades Meta on AI models and agents, sees ’meaningful headroom’
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- White House copper tariff plan stalls amid affordability concerns, sources say
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Mizuho Securities Cuts Price Target as Recent Sell-offs of Specialty Pharma Manufactures Negatively Effect Diplomat Pharmacy (DPLO)
October 21, 2015 6:43 AM EDTMizuho Securities maintained a Buy rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $44.00 (from $53.00), following recent sell-offs of specialty pharmacy manufactures. DPLO does not distribute any VRX or HZNP products. DPLO manages and distributes complex drugs for chronic conditions unlike... More
